Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: We enrolled 22 patients with metastatic DTC (16 papillary, five follicular, and one poorly differentiated) and 13 patients with MTC, of whom 15 with DTC and 10 with MTC reached first restaging. When tissue was available, eight of 15 DTC patients (53%) had B-Raf mutations; eight of 13 MTC (61.5%) patients had RET mutations. MTC partial response rate was 38% (five of 13) (duration = 9+, 12, 13, 16+, and 34+ months), stable disease of at least 6 months was 31% (four of 13). The DTC partial response rate was 4.5% (one of 22), and stable disease of at least 6 months was 36% (eight of 22). Median progression-free survival for all 35 patients was 18 months (95% confidence interval, 14.6 to not reached months). Median overall survival has not been reached, with a median follow-up of 24 months with 80% overall survival. Grade 1-2 toxicities were mainly rash, fatigue, and diarrhea. The most common grade 3-4 toxicities were rash, rise in amylase/ lipase, and fatigue. CONCLUSIONS:
|
Authors | David S Hong, Maria E Cabanillas, Jennifer Wheler, Aung Naing, Apostolia M Tsimberidou, Lei Ye, Naifa L Busaidy, Steven G Waguespack, Mike Hernandez, Adel K El Naggar, Alder K El Naggar, Savita Bidyasar, John Wright, Steven I Sherman, Razelle Kurzrock |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 96
Issue 4
Pg. 997-1005
(Apr 2011)
ISSN: 1945-7197 [Electronic] United States |
PMID | 21289252
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzenesulfonates
- Phenylurea Compounds
- Protein Kinase Inhibitors
- Pyridines
- Quinolones
- Niacinamide
- Sorafenib
- Farnesyltranstransferase
- Proto-Oncogene Proteins c-ret
- RET protein, human
- raf Kinases
- Extracellular Signal-Regulated MAP Kinases
- MAP Kinase Kinase Kinases
- Oncogene Protein p21(ras)
- tipifarnib
|
Topics |
- Adenocarcinoma, Follicular
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Benzenesulfonates
(administration & dosage, adverse effects, pharmacology)
- Carcinoma, Neuroendocrine
- Cell Differentiation
(drug effects)
- Dose-Response Relationship, Drug
- Extracellular Signal-Regulated MAP Kinases
(antagonists & inhibitors)
- Farnesyltranstransferase
(antagonists & inhibitors)
- Female
- Humans
- MAP Kinase Kinase Kinases
(antagonists & inhibitors)
- Male
- Middle Aged
- Niacinamide
(analogs & derivatives)
- Oncogene Protein p21(ras)
(antagonists & inhibitors)
- Phenylurea Compounds
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, pharmacology)
- Proto-Oncogene Proteins c-ret
(antagonists & inhibitors)
- Pyridines
(administration & dosage, adverse effects, pharmacology)
- Quinolones
(administration & dosage, adverse effects, pharmacology)
- Signal Transduction
(drug effects)
- Sorafenib
- Thyroid Neoplasms
(drug therapy, pathology)
- raf Kinases
(antagonists & inhibitors)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|